



11-646-C025

Monoclonal Antibody to CD16 Purified Antibody (0.025 mg)

Clone:	3G8
Isotype:	Mouse IgG1
Specificity:	The mouse monoclonal antibody 3G8 recognizes CD16, a low affinity receptor for aggregated IgG (FcγRIII antigen). CD16 exists in two different isoforms: CD16a (FcγRIIIA; 50-65 kDa; expressed on NK-cells, monocytes and macrophages) and CD16b (FcγRIIIB; 48 kDa; mainly expressed on neutrophils). HLDA V; WS Code NK80
Regulatory Status:	RUO
Immunogen:	Human neutrophils
Species Reactivity:	Human, Non-Human Primates
Application:	Flow Cytometry Recommended dilution: 6 µg/ml Immunoprecipitation Immunohistochemistry (frozen sections) Application note: acetone fixation Functional Application In vitro Stimulation of NK cell proliferation, blocking of IgG binding and phagocytosis, inhibition of cytotoxic activity, in vivo NK cell depletion
Purity:	> 95% (by SDS-PAGE)
Purification:	Purified by protein-A affinity chromatography
Concentration:	1 mg/ml
Storage Buffer:	Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4
Storage / Stability:	Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Expiration:	See vial label
Lot Number:	See vial label
Background:	CD16 (FcγRIII) is a 50-65 kDa glycoprotein serving as a low affinity IgG receptor. Human FcγRIII is expressed in two forms – FcγRIII-A and -B. FcγRIII-A is a transmembrane protein of monocytes, macrophages, NK cells and a subset of T cells. It is associated with FcεRI-gamma subunit and is responsible for antibody-dependent NK cell cytotoxicity. Mast cell FcγRIII-A is associated, moreover, with FcεRI-beta subunit. Besides IgG, FcγRIII-A can be triggered also by oligomeric IgE. FcγRIII-B is a GPI-linked monomeric receptor expressed on neutrophils and is involved in their activation and induction of a proadhesive phenotype.

For laboratory research only, not for drug, diagnostic or other use.

**Antibodies****References:**

- *Leukocyte Typing IV., Knapp W. et al. (Eds.), Oxford University Press (1989).
- *Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995).
- *Zhu X, Hamann KJ, Muzic NM, Rubio N, Mayer D, Herrnreiter A, Leff AR: Intracellular expression of Fc gamma RIII (CD16) and its mobilization by chemoattractants in human eosinophils. *J Immunol.* 1998 Sep 1;161(5):2574-9.
- *Metes D, Ernst LK, Chambers WH, Sulica A, Herberman RB, Morel PA: Expression of functional CD32 molecules on human NK cells is determined by an allelic polymorphism of the Fc gamma RIIC gene. *Blood.* 1998 Apr 1;91(7):2369-80.
- *Wijngaarden S, van Roon JA, van de Winkel JG, Bijlsma JW, Lafeber FP: Down-regulation of activating Fc gamma receptors on monocytes of patients with rheumatoid arthritis upon methotrexate treatment.
- *Komano Y, Nanki T, Hayashida K, Taniguchi K, Miyasaka N: Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts. *Arthritis Res Ther.* 2006;8(5):R152.
- *Choi EI, Wang R, Peterson L, Letvin NL, Reimann KA: Use of an anti-CD16 antibody for in vivo depletion of natural killer cells in rhesus macaques. *Immunology.* 2008 Jun;124(2):215-22. Epub 2008 Jan 12.
- *Congy-Jolivet N, Bolzec A, Ternant D, Ohresser M, Watier H, Thibault G: Fc gamma RIIIa expression is not increased on natural killer cells expressing the Fc gamma RIIIa-158V allotype. *Cancer Res.* 2008 Feb 15;68(4):976-80.
- *Burt BM, Plitas G, Zhao Z, Bamboat ZM, Nguyen HM, Dupont B, DeMatteo RP: The lytic potential of human liver NK cells is restricted by their limited expression of inhibitory killer Ig-like receptors. *J Immunol.* 2009 Aug 1;183(3):1789-96.
- *Jeraiby M, Sidi Yahya K, Depince-Berger AE, Lambert C: Microbicidal activity measured by flow cytometry: Optimization and standardization for detection of primary and functional deficiencies. *J Immunol Methods.* 2016 Sep 29. pii: S0022-1759(16)30220-4.
- *And many other.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.

For laboratory research only, not for drug, diagnostic or other use.

EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic
Tel: +420 261 090 666 | Fax: +420 261 090 660 | orders@exbio.cz | www.exbio.cz